Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Fosun Kite Biotechnology

Request full access

Fosun Kite Biotechnology develops immune cell therapy products

Huangpu, ChinaFounded 2017Biotech & Life Sciences

About Fosun Kite Biotechnology

Fosun Kite Biotechnology is a biopharmaceutical company focused on the development and commercialization of immune cell therapies for cancer treatment in China. The company was established in April 2017 as a 50/50 joint venture between Shanghai Fosun Pharmaceutical (Group) Co., Ltd., a leading Chinese healthcare group, and Kite Pharma, a US-based Gilead Sciences company and a pioneer in cell therapy. In September 2024, Fosun Pharma acquired Kite's 50% stake, making Fosun Kite a wholly-owned subsidiary, set to be renamed Fosun Kairui. Despite the buyout, the two will maintain a long-term strategic partnership through licensing agreements.

The company's primary business involves localizing, manufacturing, and commercializing advanced cell therapies. Its business model centers on licensing cutting-edge products, conducting local clinical trials for regulatory approval, and then manufacturing and selling these therapies in the Greater China region. A major milestone was achieved in June 2021 when its lead product, Axicabtagene Ciloleucel (brand name: Yikaida®), became the first CAR-T cell therapy approved by China's National Medical Products Administration (NMPA). This personalized therapy genetically modifies a patient's own T-cells to recognize and attack cancer cells. It is approved for adult patients with relapsed or refractory large B-cell lymphoma (LBCL) after two or more lines of systemic therapy. The company is also developing FKC889 for relapsed or refractory mantle cell lymphoma (MCL) and is exploring therapies for solid tumors.

Headquartered in Shanghai, Fosun Kite operates a commercial manufacturing facility and an R&D center in the Zhangjiang Hi-Tech Park. The company serves cancer patients who have exhausted conventional treatment options. Given the high cost of CAR-T therapy, which is priced at around 1.2 million yuan (about $170,000) in China, the company is actively exploring innovative payment models and partnerships with commercial and government-supplemented insurance programs to improve patient access. In 2023, Fosun Kite generated revenues of 242 million Chinese yuan ($34 million).

Source: Dealroom company data

At a glance

Status
Operational
Employees
79
Open positions
1
Dealroom signal
40.5/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES AOther financing Oct 2025 $89M $303M Pingshan District Industrial Capital Investment · Fosun Health Capital ↗
LATE VCOther financing Jul 2020 $20M $80M Kite Pharma —
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Fosun Kite Biotechnology website traffic

Latest recorded traffic for Fosun Kite Biotechnology is 0 monthly website visits, down 100% over the last three months. Fosun Kite Biotechnology's team grew 0% over the past year.

Latest monthly visits0 3-month web change-100% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Fosun Kite Biotechnology in the Huangpu ecosystem

Live from Dealroom

The Fosun Kite Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

3 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

  • Pingshan District Industrial Capital Investment
  • Fosun Health Capital

Series B and later1 investor entered at this stage

  • Kite Pharma
Team profiled 1 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇨🇳 China100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Fosun Kite Biotechnology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Fosun Kite Biotechnology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.